IOVA: Iovance Biotherapeutics, Inc. Common Stock Company Profile & Statistics

Iovance Biotherapeutics, Inc. Common Stock Profile

About

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Info & Links

CEO

Frederick G. Vogt

Headquarters

825 INDUSTRIAL ROAD, SUITE 100
SAN CARLOS, CA 94070, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

975

Iovance Biotherapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

1.45B

Enterprise Value

1.28B

Enterprise Value/EBITDA(ttm)

-3.54

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

5.86

Price to Book(mrq)

2.13

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

28.75%

Operating Margin(ttm)

-148.41%

Profit Margin(ttm)

-159.98%

Return on Equity(ttm)

-54.54%

Return on Invested Capital(ttm)

-54.40%

Return on Assets(ttm)

-42.36%

Income Statement

Revenue(ttm)

263.50M

Revenue Per Share(ttm)

0.64

Gross Profit(ttm)

90.32M

EBITDA(ttm)³

-363.23M

Net Income Available to Common(ttm)

-390.98M

Diluted EPS(ttm)

-1.12

Share Statistics

Beta (5Y Monthly)

0.69

52-Week Change

2.47%

S&P 500 52-Week Change

11.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

411.96M

Dividend Yield

0.00%

Float⁴

369.53M

% Held by Insiders

10.30%

% Held by Institutions

77.03%

Balance Sheet

Total Cash(mrq)

296.98M

Total Cash Per Share(mrq)

0.72

Total Debt(mrq)

1000.00K

Total Debt/Equity(mrq)

0.14%

Current Ratio(mrq)

3.20%

Quick Ratio(mrq)

2.83%

Book Value Per Share(mrq)

1.70

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.85

Free Cash Flow(ytd)

-336.24M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

IOVA

Iovance Biotherapeutics, Inc. Common Stock